Claims for Patent: 11,260,078

Summary for Patent: 11,260,078

Title:	Method of treating senescence with multi-stage longevity therapeutics
Abstract:	A method of treating senescence in a subject can include applying a senoremediation drug treatment protocol to the subject in order to rescue one or more first cells in the subject, wherein the senoremediation drug treatment protocol is derived from a computational transcriptome analysis of the tissue or organ of the subject. The method can include applying a senolytic drug treatment protocol to the subject in order to remove one or more second cells in the subject. The method can include introducing stem cells into a tissue and/or organ of the subject in order to rejuvenate one or more tissue cells in the tissue and/or one or more organ cells in the organ. The method can include carrying out a reinforcement step that includes one or more actions that prevent further senescence or degradation of the tissue or organ.
Inventor(s):	Aleksandr M. Aliper, Aleksandrs Zavoronkovs, Ivan Ozerov, Marine E. Bozdaganyan, Artem V. Artemov
Assignee:	InSilico Medicine IP Ltd
Application Number:	US16/044,784

Details for Patent 11,260,078

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Biologicals	SHINGRIX	zoster vaccine recombinant, adjuvanted	Injection	125614	October 20, 2017		2038-07-25
Glaxosmithkline Biologicals	SHINGRIX	zoster vaccine recombinant, adjuvanted	For Injection	125614	July 23, 2021		2038-07-25

International Patent Family for US Patent 11,260,078

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2022058980
World Intellectual Property Organization (WIPO)	2021240263
World Intellectual Property Organization (WIPO)	2020234729